Jasper Therapeutics, Inc. (JSPRW) — SEC Filings
Jasper Therapeutics, Inc. (JSPRW) — 39 SEC filings. Latest: 8-K (Dec 2, 2025). Includes 16 8-K, 7 SC 13G/A, 6 10-Q.
View Jasper Therapeutics, Inc. on SEC EDGAR
Overview
Jasper Therapeutics, Inc. (JSPRW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: Jasper Therapeutics, Inc. (JSPRW) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $66.7 million, up from $46.9 million in the same period of 2024. This 42.2% increase was primarily driven by a substantial rise in research and development expenses, w
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 2 bearish, 35 neutral, 2 mixed. The dominant filing sentiment for Jasper Therapeutics, Inc. is neutral.
Filing Type Overview
Jasper Therapeutics, Inc. (JSPRW) has filed 16 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 3 SC 13G, 1 DEFA14A, 2 SC 13D/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of JSPRW's 25 recent filings, 2 were flagged as high-risk, 6 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | $ -66.7M |
| EPS | $ -4.18 |
| Cash Position | $ 50.9M |
| Total Assets | $ 57.5M |
| Total Debt | $ 45.9M |
Key Executives
- Dr. Jonathan Leipsic
- Ms. Sarah K. Johnson
- Jeffrey Ferguson
- Adam Morgan
Industry Context
Jasper Therapeutics operates in the biotechnology sector, a highly competitive and capital-intensive industry focused on developing novel therapeutics. The sector is characterized by long development cycles, high failure rates, and significant reliance on external funding for research and development. Companies often face intense competition from both established pharmaceutical giants and emerging biotechs, necessitating continuous innovation and strategic partnerships.
Top Tags
biotech (6) · corporate-governance (5) · amendment (5) · 10-Q (4) · Biotechnology (3) · corporate-action (3) · Clinical Stage (2) · Going Concern (2) · Cash Burn (2) · R&D Expenses (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $66.7M | Increased 42.2% for nine months ended Sep 30, 2025, from $46.9M in 2024. |
| Cash and Cash Equivalents | $50.9M | Decreased from $71.6M at Dec 31, 2024, indicating significant cash burn. |
| Net Cash Used in Operating Activities | $55.3M | Increased from $41.5M in 2024, highlighting growing operational cash burn. |
| Research and Development Expenses | $51.7M | Increased from $36.0M in 2024, driving higher operating losses. |
| Accumulated Deficit | $307.6M | As of September 30, 2025, reflecting substantial historical losses. |
| Warrant Liability | $22.6M | New liability recognized from an underwritten offering, impacting balance sheet. |
| Common Stock Shares Outstanding | 27,984,039 | Increased from 15,022,122 at Dec 31, 2024, indicating significant dilution. |
| Net Cash Provided by Financing Activities | $34.6M | Raised through offerings, but insufficient to cover cash burn. |
| Net Loss (Q2 2025) | $26.7M | Increased 83% from $14.6M in Q2 2024 |
| Net Loss (H1 2025) | $48.0M | Increased 69.9% from $28.3M in H1 2024 |
| R&D Expenses (H1 2025) | $37.4M | Increased from $21.6M in H1 2024 |
| Cash & Equivalents (June 30, 2025) | $39.5M | Decreased from $71.6M at Dec 31, 2024 |
| Accumulated Deficit (June 30, 2025) | $288.8M | Indicates significant historical losses |
| Cash Used in Operations (H1 2025) | $38.3M | Increased from $27.4M in H1 2024 |
| Common Shares Outstanding (June 30, 2025) | 16,219,243 | Increased from 15,022,122 at Dec 31, 2024, partly due to ATM offering |
Forward-Looking Statements
- {"claim":"Velan Capital will likely engage in discussions with Jasper Therapeutics' management or board.","entity":"Velan Capital Investment Management LP","targetDate":"Q2 2024","confidence":"high"}
- {"claim":"Jasper Therapeutics' stock price may experience increased volatility due to activist investor involvement.","entity":"Jasper Therapeutics, Inc.","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Jasper Therapeutics, Inc. (JSPRW)?
Jasper Therapeutics, Inc. has 39 recent SEC filings from Jan 2024 to Dec 2025, including 16 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of JSPRW filings?
Across 39 filings, the sentiment breakdown is: 2 bearish, 35 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Jasper Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Jasper Therapeutics, Inc. (JSPRW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Jasper Therapeutics, Inc.?
Key financial highlights from Jasper Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for JSPRW?
The investment thesis for JSPRW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Jasper Therapeutics, Inc.?
Key executives identified across Jasper Therapeutics, Inc.'s filings include Dr. Jonathan Leipsic, Ms. Sarah K. Johnson, Jeffrey Ferguson, Adam Morgan.
What are the main risk factors for Jasper Therapeutics, Inc. stock?
Of JSPRW's 25 assessed filings, 2 were flagged high-risk, 6 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Jasper Therapeutics, Inc.?
Recent forward-looking statements from Jasper Therapeutics, Inc. include guidance on {"claim":"Velan Capital will likely engage in discussions with Jasper Therapeutics' management or board.","entity":"Vela and 1 other predictions.